CD8A and neoplasm: They demonstrated significant activity in reducing the number of MDSCs from the TME or inhibiting their suppressive activity against CD8+ T cells, which leads to the inhibition of tumor growth or metastasis [21,22,29,33], prolongation of survival [31], attenuation of the growth-promoting effect of E2 [33], or enhancement of the efficacies of existing anticancer treatments, including cisplatin therapy [28] or radiotherapy [21].